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Abstract 
Background: Data on PNM elastase levels in cerebrospinal fluid following traumatic brain injury (TBI) in humans 
are not available in the literature. Therefore, the aim of this prospective study was to evaluate the dynamics of PMN 
elastase in the cerebrospinal fluid (CSF) of patients after TBI.
Methods: Patients suffering from isolated, closed TBI, presenting with an initial Glasgow coma score ≤ 8 and with 
intracerebral hemorrhage on the initial cranial computed tomography scan (performed within 90 min after TBI) were 
enrolled. CSF and blood samples were obtained immediately, 12 h, 24 h, 48 h, and 72 h after admission. ELISA testing 
was used to quantify the PMN elastase levels in CSF. In addition, the ratio of CSF albumin to serum albumin was calcu-
lated to evaluate the role of the blood–cerebrospinal fluid barrier (BCSFB). As controls, CSF samples were taken from 
patients receiving spinal anesthesia for elective orthopedic surgery of the lower extremity.
Results: Twenty-three patients meeting the inclusion criteria and ten control patients were enrolled. The PMN 
elastase showed a significant elevation at 48 and 72 h after TBI. When comparing the PMN elastase levels of patients 
with intact BCSFB to patients with defective BCSFB, there was no significant difference for the respective observation 
points.
Conclusions: This is the first study to demonstrate that the PMN elastase levels in CSF significantly increased in the 
early posttraumatic phase (48 h and 72 h after TBI) in patients. The function of the BCSFB showed no significant influ-
ence on the PMN levels.
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Background
Traumatic brain injury (TBI) often affects young adults 
and is a major cause of persistent neurocognitive impair-
ment in this age group [1]. In general, the severity of the 
primary traumatic injury and the extent of the second-
ary biomolecular injury cascades determine the outcome 
[2]. Since these secondary injuries might be responsible 
for the development of neurological deficits, they might 
serve as a potential target in the development of new 
therapeutic interventions [3]. In this context, it seems 
crucial to further explore and understand the intracranial 
processes following TBI [3].
Granulocytes or polymorphonuclear (PMN) leukocytes 
have granules in their cytoplasm which contain elastase 
that can be secreted. This so-called PMN elastase is 
involved in the extracellular immune defense of microor-
ganisms. Its activity in the extracellular space is regulated 
by the formation of alpha 1-proteinase inhibitor–elastase 
complexes. Consequently, the level of inhibitor–elastase 
complexes correlates with the elastase that is actually 
secreted [4]. Severe inflammatory conditions can lead to 
an overload of the human immune system and elastase, 
especially in combination with oxidants (e.g.,  H2O2,  O2 
radicals), which can lead to tissue damage.
Under physiological conditions, the cerebrospinal fluid 
(CSF) is separated from peripheral and cerebral blood 
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flow by the blood–cerebrospinal fluid barrier (BCSFB). 
When analyzing the dynamics of the PMN elastase in 
CSF of TBI patients the question arises whether changes 
in CSF fractions occur due to a disrupted BCSFB or due 
to other mechanisms. The leukocyte count in CSF is far 
lower than in peripheral blood. A damaged BCSFB could, 
therefore, possibly lead to an increase in the number of 
granulocytes in the CSF via cell leakage due to disturbed 
blood vessels. Consequently, PMN elastase secretion 
would be enhanced resulting in an increased level. Thus, 
it is necessary to take the function of the BCSFB into 
account when evaluating the PMN elastase.
It is well known that the proteinase PMN elastase plays 
an important role in acute injury and inflammation [5–
8]. However, data on PNM elastase levels in cerebrospi-
nal fluid following TBI in humans are not available in the 
literature.
Therefore, the aim of the present study was to evaluate 
the dynamics of PMN elastase in the CSF of patients with 
TBI from the time of admission until 72  h afterwards. 
The first null hypothesis was that there was no difference 
between the CSF levels of patients at the various sam-
ple points. Second null hypothesis postulated that there 
was no difference between the CSF values of the patients 
(with TBI) and the control group. The influence of the 
BCSFB was investigated by distinguishing two groups of 
patients with TBI: those with an intact and those with a 
defective BCSFB. The level of significance was set to 0.05.
Patients and methods
Study design and patient population
Patients suffering from closed, isolated TBI, who pre-
sented with an initial Glasgow coma score (GCS) ≤ 8 
points (i.e., severe brain injury) and radiological signs of 
an intracerebral hemorrhage (ICH) on the initial cranial 
CT scan (performed within 90 min after TBI) were pro-
spectively enrolled. Patients with an untreatable brain 
swelling and/or brain stem herniation were excluded. A 
history of pre-existing neurological, malignant or chronic 
inflammatory disease led to exclusion as well. Written 
informed consent was obtained as soon as the patient 
regained consciousness. In case of remaining uncon-
scious, either a legal representative or a next of kin was 
asked for the (supposed) will of the patient. As controls, 
CSF samples were taken from patients receiving spinal 
anesthesia for elective orthopedic surgery of the lower 
extremity. The study was approved by the University 
Institutional Review Board (Reference no. 330/03).
Treatment
Patients were treated in accordance with the guidelines 
of the Brain Trauma Foundation [9]. An extraventricular 
drain (TraumaCath, Integra Neurosciences; Plainsboro, 
USA) was positioned in the frontal horn of the lateral 
ventricle to obtain CSF for further analysis and to con-
tinuously monitor the patient’s intracranial pressure 
(ICP) [10]. After the procedure, a CT scan was per-
formed to verify the position of the drain. As soon as the 
ICP remained at a level of maximal 15 mmHg for at least 
72  h—without CSF drainage or mannitol administra-
tion—the drain was removed.
Sampling
The first sample was drawn immediately after the place-
ment of the intraventricular drain within 90 ± 45  min 
after admission to the hospital. Further sampling points 
were at 12, 24, 48 and 72  h after TBI. Approximately 
4 ml of CSF and 5 ml of peripheral serum were collected 
at each sampling point. 500  µl of liquor and peripheral 
serum was sent to the department of hematology to 
determine the respective albumin levels there. For the 
enzyme-linked immunosorbent assay (ELISA) analy-
sis, the CSF samples were centrifuged for 10  min with 
1200g at 4 °C. Afterwards, the supernatant was frozen at 
− 80 °C.
Analysis of PMN elastase concentration in CSF
An enzyme immunoassay (Milena Biotech, Bad Nauheim, 
Germany) was used for the quantitative measurement of 
the human PMN elastase. The assay contained the fol-
lowing components:
1. divisible microplate removable wells, coated with 
polyclonal antibodies (egg yolk) against PMN 
elastase;
2. PMN elastase master calibrator in serum/buffer 
matrix, containing PMN elastase–α1PI complex;
3. PMN elastase controls in serum/buffer matrix;
4. PMN elastase calibrator/sample diluent;
5. enzyme-labeled anti-α1PI antibody, containing poly-
clonal rabbit antibodies, labeled with horseradish 
peroxidase;
6. TMB-substrate solution (3,3′,5,5′-tetra-methyl-ben-
zidine) in buffered peroxide solution;
7. stop solution, containing 2 M hydrochloric acid;
8. wash buffer concentrate (10×).
The sampling material was thawed at 20  °C for analy-
sis. Thirty minutes before use, the PMN elastase master 
calibrator (Milena Biotech, Bad Nauheim, Germany) 
and the PMN elastase controls (Milena Biotech, Bad 
Nauheim, Germany) were each reconstituted with 2  ml 
calibrator/sample diluent (Milena Biotech, Bad Nauheim, 
Germany). The calibrators were prepared with a two-
fold dilution series (1000  ng/ml, 500  ng/ml, 250  ng/ml, 
125  ng/ml, 62.5  ng/ml, 31.3  ng/ml and 15.6  ng/ml). All 
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patient samples were diluted with a ratio of 1:100 using 
calibrator/sample buffer (Milena Biotech, Bad Nauheim, 
Germany). Subsequently, 100  µl of prediluted patient 
samples, calibrators, and controls was pipetted into the 
microplate’s wells, according to the assay’s template 
(Milena Biotech, Bad Nauheim, Germany). This was fol-
lowed by an incubation period of 60  min at 20  °C on a 
plate mixer with 400 rpm. Afterwards, the samples were 
washed four times using 300  µl buffered wash solution 
(Milena Biotech, Bad Nauheim, Germany). Subsequently, 
150  µl of enzyme-labeled anti-α1PI antibodies (Milena 
Biotech, Bad Nauheim, Germany) was added. The sec-
ond incubation period of 60 min at 20 °C on a plate mixer 
with 400 rpm led to the formation of so-called “sandwich” 
complexes. After repeated fourfold washing using 300 µl 
buffered wash solution (Milena Biotech, Bad Nauheim, 
Germany), 200 µl of TMB in buffered peroxide solution 
(Milena Biotech, Bad Nauheim, Germany) was added. 
This was followed by an incubation period of 20  min 
in the dark at 20 °C. 50 µl of 2 M hydrochloric acid was 
added before the sample was thoroughly mixed. Finally, 
the produced yellow signal was measured at a wavelength 
of 450 nm. Using a standard curve, the concentration of 
the PMN elastase could be determined from the signal.
Assessment of blood–cerebrospinal fluid barrier (BCSFB) 
function
Reiber and Felgenhauer were able to show that the ratio 
of albumin in CSF and serum (Qalb) is a sensitive param-
eter for the analysis of BCSFB integrity [11]: values less 
or equal to 0.01 indicate an intact BCSFB, whereas values 
> 0.01 are considered to occur only in defective BCSFB. 
In our study, Qalb was calculated at each observing point 
to assess the function of the BCSFB. Standardized turbi-
dimetric assays (Cobas  Integra® Albumin,  Roche® Diag-
nostics, Mannheim, Germany) were used to determine 
the albumin levels in the CSF and the serum. The enrolled 
patients were divided into two groups to assess the influ-
ence of the BCSFB function on PMN elastase: group 1 
with an intact and group 2 with a defective BCSFB.
Data analysis
The Sigma  Stat® 3.0 software package  (SPSS® Inc., Chi-
cago, USA) was used for all statistical analyses. Data were 
mostly provided in mean ± SEM. For non-parametric 
data, ANOVA (analysis of variance on ranks) according 
to Kruskal–Wallis was used to compare the values of the 
different groups. To analyze differences over the course 
of time, the Student–Neumann–Keuls test was applied 
after ANOVA. A p value < 0.05 was considered statisti-
cally significant.
Results
Patient population and clinical data
23 patients suffering from isolated severe TBI met the 
initial inclusion criteria. The mean age accounted for 
46 ± 5  years. Eight patients died during the observa-
tion period of 72  h due to untreatable brain swell-
ing and/or brain stem herniation and were, therefore, 
excluded. In total, 15 patients (5 females, 10 males) were 
finally enrolled in the study. Local or systemic infec-
tions were not observed during the observation period 
of 72 h. Among these 15 patients, three died later from 
their severe injuries (Table 1). The main reasons for TBI 
were either road traffic accidents or falling from a great 
height. Ten (5 females, 5 males) patients with a mean age 
of 40 ± 11 years were included in the control group. All 
patients had no records of CNS disease or trauma. In 
the control group, CSF was obtained while the patients 
received spinal anesthesia for a standard elective ortho-
pedic procedure of the lower extremity.
Dynamics of the PMN elastase in the early posttraumatic 
phase
Over the entire observation period of 72 h a continuous 
increase of PMN elastase was found. Starting at levels of 
4.97 ± 1.9  ng/ml on admission the increase resulted in 
9.33 ± 1.7 ng/ml at 12 h after TBI, 27.12 ± 10.6 ng/ml at 
48 h and 57.10 ± 21.5 ng/ml at 72 h after TBI.
The baseline level of the control group accounted for 
3.68 ng/ml. Compared to the level measured immediately 
after admission (4.97  ng/ml), the first significant eleva-
tion of PMN elastase was registered 48  h after trauma 
(27.12  ng/ml at 48  h; p = 0.041). Similarly, the levels of 
PMN elastase at 48 (p = 0.042) and at 72  h (p = 0.036) 
after TBI (see above) were significantly higher compared 
to the baseline level of the control group (3.68  ng/ml). 
For more details, see Table 2 and Fig. 1.
Dynamics of PMN elastase on dependence of BCSFB 
function
At the time of admission, patients of group I (n = 9) 
with an intact BCSFBB showed a PMN elastase level of 
2.93 ± 1.9  ng/ml and patients of group II (n = 6) with 
a defective BCSFBB presented a level of 8.80 ± 4.2 ng/
ml. 12 h after TBI group I had a PMN elastase level of 
3.87 ± 2.5  ng/ml while group II patients had a PMN 
elastase level of 11.72 ± 4.3  ng/ml. Group I patients 
showed a PMN elastase level of 8.2 ± 2.1 ng/ml at 24 h 
after TBI while group II patients presented a level 
of 9.80 ± 3.5  ng/ml. 48  h after trauma group I had a 
PNM elastase level of 14.56 ± 3.8  ng/ml and group II 
presented a level of 45.26 ± 26.6  ng/ml. At the obser-
vation end point of 72  h the elastase level of group I 
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was 58.56 ± 32.6  ng/ml whereas the elastase level of 
group II patients accounted for 50.00 ± 27.1  ng/ml. In 
summary, both groups presented an increase of PMN 
elastase levels over time. Comparing the PMN elastase 
levels of groups I and II at the sample time points no 
significant difference could be found.
However, further analysis revealed significantly dif-
ferent PMN elastase levels in group I when comparing 
the level at time of admission to the levels at 48 as well 
as 72 h, respectively.
The control group presented a PMN elastase level of 
3.68 ± 0.3  ng/ml. Comparing the control level to the 
PMN elastase values of group I and II significant dif-
ferences were found at 48  h after TBI. The same find-
ings resulted in comparing the control group level to 
patients’ levels with intact as well as defective BCSFBB 
Table 1 Demographic and clinical data of patients
EDH epidural hematoma, EVD extraventricular drain, ICB intracerebral bleeding, ORIF open reduction and internal fixation, SAH subarachnoidal hemorrhage, SDH 
subdural hematoma
BCSFB function Patient no. Age (years) Sex Injury Intervention Survival
Intact I 32 f SAH, SDH EVD Yes
Intact II 82 m SAH, SDH, longitudinal fracture of the 
petrous part of temporal bone, contu-
sion bleeding
EVD Yes
Intact III 43 m EDH, SAH EVD, osteoclastic craniotomy, removal of 
hematoma
Yes
Intact IV 23 m SAH, contusion bleeding, impression frac-
ture, intracranial foreign bodies
EVD, osteoclastic craniotomy No
Intact V 20 m ICB, midface fracture EVD, ORIF Yes
Intact VI 48 m Cerebellar ICB, SDH EVD, occipital craniotomy Yes
Intact VII 54 m SAH EVD Yes
Intact VIII 50 f SAH, ICB, impression fracture EVD, osteoclastic craniotomy No
Intact IX 34 m SAH, longitudinal fracture of the petrous 
part of temporal bone, frontobasal 
fracture
EVD Yes
Defective X 50 m ICB, SAH, skull base fracture, occipital bone 
fracture, orbital fracture
EVD Yes
Defective XI 27 f SDH, SAH, contusion bleeding, impression 
fracture, temporal bone fracture
EVD, osteoclastic craniotomy No
Defective XII 41 f SAH, SDH, skull base fracture EVD Yes
Defective XIII 62 m SDH, EDH, SAH, skull fracture EV, osteoclastic craniotomy Yes
Defective XIV 67 m EDH, ICB, SAH, skull base fracture, occipital 
bone fracture, fracture of the petrous 
part of temporal bone
EVD, osteoclastic craniotomy, removal of 
hematoma
Yes
Defective XV 69 f ICB, SAH EVD, osteoclastic craniotomy Yes
Table 2 Dynamics of the PMN elastase in CSF
T0 = within 90 ± 45 min after admission; * p < 0.05 versus control group; # p < 0.05 versus study group at T0. PMN elastase in ng per ml in CSF (study group: n = 15; 
control group: n = 10; mean value ± standard error of the mean)
Time after trauma (h) Control T0 12 h 24 h 48 h 72 h
PMN elastase (ng/ml) 3.68 ± 0.3 4.97 ± 1.9 7.33 ± 2.3 9.33 ± 1.7 27.12 ± 10.6*,# 57.10 ± 21.5*,#
Fig. 1 Dynamics of the PMN elastase in CSF. The y-axis shows the 
values of PMN elastase in ng/ml in the CSF (mean ± SEM). The 
respective sampling points are shown on the x-axis
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at the 72-h time point. For a summary of values, see 
Table 3.
Discussion
The actual study evaluated for the first time the dynam-
ics of PMN elastase in cerebrospinal fluid of patients 
suffering from traumatic brain injury in the direct post-
traumatic phase. PMN elastase levels were significantly 
elevated at 48 and 72 h compared to PMN levels at time 
of admission to the hospital as well as compared to base-
line levels of the control group.
PMN elastase is involved in the shedding of tumor 
necrosis factor receptors from stimulated granulocytes 
[12]. In addition, the concentration of PMN elastase can 
be used as an activity marker for the function of granulo-
cytes [4]. Therefore, the evaluation of the release kinet-
ics of the PMN elastase is of high relevance regarding its 
involvement in secondary brain damage.
In our study, a comparison of PMN elastase levels in 
patients with intact and defective BCSFB showed no 
significant difference for the different observation time 
points. This might indicate that the influx of neutro-
philic cells via the BCSFB was regulated in both groups. 
This would be in line with the literature—the BCSFB is 
seen as selective immune cell trafficking gate with active 
immune-regulating mechanisms [13, 14]. Several stud-
ies have explored the mechanisms of neutrophil migra-
tion over the BCSFB after TBI in animal models [13, 
15, 16]. It has been shown that the BCSFB produces 
CXC chemokines [15] which have neutrophil chemot-
actic activity and modulate neutrophil trafficking [17]. 
Recently, it has been reported that the hormone arginine 
vasopressin (AVP) enhances the posttraumatic influx of 
neutrophils across the BCSFB via activating the c-Jun 
N-terminal kinase (JNK) [16].
Various mechanisms could serve as potential targets 
for therapeutic interventions to reduce brain tissue dam-
age and to improve the functional neurological outcome 
of the patient. In this context, the in  vivo inhibition of 
JNK in rats significantly reduced the production of neu-
trophil chemoattractants by the BCSFB and significantly 
reduced the influx of neutrophils across the BCSFB [16].
Very recently, the inhibition of PMN elastase with sive-
lestat (ONO 5046) gained attention in the treatment of 
ischemic spinal cord injury, traumatic spinal cord injury 
and ischemic brain injury [18–20]. The administration 
of sivelestat leads to a better outcome in animal models 
such as rabbits [19] and rats [18, 20]. Unfortunately, the 
literature does not provide any studies using sivelestat 
after TBI. However, a study on knockout mice reported 
that the PMN elastase has a central role in acute patho-
genesis and chronic functional recovery after TBI of 
the immature brain [21]. This study also confirmed that 
the treatment of wild-type mice with the PMN elastase 
inhibitor ZN200,355 (AstraZeneca, London, UK) at 
2-, 6- and 12-h post-TBI resulted in a reduction of cell 
death and oxidative stress [21]. The results of these stud-
ies point out that further research is necessary to explore 
the effects of PMN elastase inhibition in an adult animal 
model. For acute lung injuries, the positive effect of inhib-
iting PMN elastase had already been detected 30  years 
ago [22]. However, it had taken decades of basic research 
until sivelestat was approved in Japan for the treatment 
of acute lung injuries. Recent studies confirm benefits 
of sivelestat administration for patients after acute lung 
injury [23, 24]. Analogous to TBI research, this points 
out that further basic research concerning PMN elastase 
might be valuable and is necessary.
It is important to describe which other factors may 
have stimulated the release of PMN elastase in CSF. Sys-
temic infections could have caused an increase in PMN 
elastase, but none were observed in our patients. Local 
infections, especially bacterial infections, could also have 
stimulated the release of PMN elastase. No evidence 
of local infection was found in our patient population. 
However, it cannot be completely ruled out that bacteria 
were present.
The presented study owns several limitations. First, the 
levels of PMN elastase were measured and significant 
elevations were found, but the reasons for the elevations 
were not further evaluated. However, this is the focus of 
our ongoing research. Since the placement of a ventric-
ular drainage always leads to some kind of brain injury, 
an increase of the elastase levels might also be caused 
by the therapeutic intervention itself. However, by com-
paring the results of the patients to those of the control 
group, our results show that brain injury leads to a sig-
nificant increase of PMN elastase. For future studies, a 
second control group, receiving an extraventricular drain 
for different reasons than for TBI, should be considered. 
Table 3 Dynamics of the PMN elastase in CSF in dependence of the BCSFB function
T0 = within 90 ± 45 min after admission; * p < 0.05 versus control group; # p < 0.05 versus same group at T0. PMN elastase in ng per ml in CSF (group I with intact BCSFB: 
n = 9; group II with defective BCSFB: n = 6; control group: n = 10; mean value ± standard error of the mean)
Time after Trauma (h) Control T0 12 h 24 h 48 h 72 h
Group I PMN Elastase (ng/ml) 3.68 ± 0.3 2.93 ± 1.9 3.87 ± 2.5 8.2 ± 2.1 14.56 ± 3.8*,# 58.56 ± 32.6*,#
Group II PMN Elastase (ng/ml) 3.68 ± 0.3 8.80 ± 4.2 11.72 ± 4.3 9.80 ± 3.5 45.26 ± 26.6* 50.00 ± 27.1*
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Finally, groups I and II were both very small, hence the 
interpretation regarding BCSFB function should not be 
overestimated.
Conclusions
This is the first study that demonstrates that the PMN 
elastase becomes significantly elevated 48  h and 72  h 
after TBI in patients. Assessment of the BCSFB could 
not reveal any significant influence of its function on 
the PMN levels. Future clinical studies should evaluate 
whether the elevation of PMN elastase affects not only 
the outcome of animals but also of patients. This is the 
focus of the current research of our study group.
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